Publicaciones en colaboración con investigadores/as de Hospital General Universitario de Valencia (12)

2023

  1. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 1, pp. 57-64

  2. Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage

    Actas Dermo-Sifiliograficas

  3. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. 291-298

2022

  1. EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and Sézary syndrome: Real-world data in Spanish patients (MICADOS Study)

    JEADV Clinical Practice, Vol. 1, Núm. 4, pp. 438-449

2021

  1. EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and Sézary syndrome: real-world data in Spanish patients (MICADOS study)

    European Journal of Cancer, Vol. 156, pp. S29-S30

  2. Patients with primary cutaneous lymphoma are at risk for severe COVID-19. Data from the Spanish Primary Cutaneous Lymphoma Registry

    Journal of the European Academy of Dermatology and Venereology

2020

  1. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways

    British Journal of Dermatology, Vol. 182, Núm. 1, pp. 147-155

2018

  1. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas

    British Journal of Dermatology

  2. Association of APOA5 and APOC3 Genetic Polymorphisms with Severity of Hypertriglyceridemia in Patients with Cutaneous T-Cell Lymphoma Treated with Bexarotene

    JAMA Dermatology, Vol. 154, Núm. 12, pp. 1424-1431

  3. The First Year of the AEVD Primary Cutaneous Lymphoma Registry

    Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 610-616

2016

  1. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome

    British Journal of Dermatology, Vol. 175, Núm. 1, pp. 80-88

2015

  1. MicroRNA Expression Profiling and DNA Methylation Signature for Deregulated MicroRNA in Cutaneous T-Cell Lymphoma

    Journal of Investigative Dermatology, Vol. 135, Núm. 4, pp. 1128-1137